OAM
GNOM icon

Oppenheimer Asset Management’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Oppenheimer Asset Management’s Portfolio GNOM Stock Details GNOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$767K Sell
17,539
-3,493
-17% -$162K 0.01% 788
2025
Q4 		$956K Sell
21,032
-1,009
-5% -$44.7K 0.01% 682
2025
Q3 		$856K Sell
22,041
-367
-2% -$13.3K 0.01% 792
2025
Q2 		$756K Buy
22,408
+1,677
+8% +$53.1K 0.01% 796
2025
Q1 		$659K Buy
20,731
+5,462
+36% +$207K 0.01% 800
2024
Q4 		$593K Sell
15,269
-159
-1% -$6.68K 0.01% 829
2024
Q3 		$694K Sell
15,428
-1,500
-9% -$67.1K 0.01% 803
2024
Q2 		$707K Buy
16,928
+1,565
+10% +$65.4K 0.01% 781
2024
Q1 		$699K Sell
15,363
-263
-2% -$12K 0.01% 767
2023
Q4 		$722K Buy
15,626
+2,097
+16% +$85.5K 0.01% 782
2023
Q3 		$550K Buy
13,529
+1,400
+12% +$63.7K 0.01% 827
2023
Q2 		$588K Buy
12,129
+367
+3% +$18.4K 0.01% 822
2023
Q1 		$580K Buy
11,762
+608
+5% +$31.3K 0.01% 815
2022
Q4 		$564K Sell
11,154
-491
-4% -$25.3K 0.01% 820
2022
Q3 		$585K Buy
11,645
+48
+0.4% +$2.71K 0.01% 794
2022
Q2 		$567K Buy
11,597
+378
+3% +$19.2K 0.01% 825
2022
Q1 		$674K Buy
11,219
+2,402
+27% +$151K 0.01% 849
2021
Q4 		$700K Buy
8,817
+1,628
+23% +$137K 0.01% 879
2021
Q3 		$637K Buy
7,189
+1,486
+26% +$139K 0.01% 870
2021
Q2 		$568K Buy
5,703
+1,198
+27% +$106K 0.01% 914
2021
Q1 		$405K Buy
+4,505
New +$445K 0.01% 969

Other funds holding GNOM

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
AA
Armis Advisers Atlanta, Georgia $1.09B AUM 22.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $1.65B AUM 15.6% 1-Year Est. Return
SWA
Sightline Wealth Advisors Groton, Connecticut $273M AUM 18.08% 1-Year Est. Return

Oppenheimer Asset Management's GNOM Position: Q1 2026 in Review

Oppenheimer Asset Management reduced its Global X Genomics & Biotechnology ETF (GNOM) stake by 17% in Q1 2026, selling an estimated $162K and leaving 17,539 shares worth $767K. The position accounts for 0.01% of the portfolio, ranked #788.

Oppenheimer Asset Management first reported a position in GNOM in Q1 2021 and has held it in 21 quarters since. The position peaked at $956K in Q4 2025. 40 funds tracked by Wall St. Rank hold GNOM as of Q1 2026.

  • Oppenheimer Asset Management held 17,539 shares of Global X Genomics & Biotechnology ETF worth $767K as of Q1 2026.
  • Oppenheimer Asset Management sold 3,493 Global X Genomics & Biotechnology ETF shares in Q1 2026, an estimated $162K.
  • Global X Genomics & Biotechnology ETF made up 0.01% of Oppenheimer Asset Management's portfolio in Q1 2026, its #788 holding.
  • Oppenheimer Asset Management first reported a position in Global X Genomics & Biotechnology ETF in Q1 2021 and has held it in 21 quarters since.
  • Oppenheimer Asset Management's Global X Genomics & Biotechnology ETF position peaked at $956K in Q4 2025.
  • 40 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q1 2026.

Based on Oppenheimer Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.